Edition:
United Kingdom

Takeda Pharmaceutical Co Ltd (4502.T)

4502.T on Tokyo Stock Exchange

3,943JPY
17 Dec 2018
Change (% chg)

¥-38 (-0.95%)
Prev Close
¥3,981
Open
¥3,934
Day's High
¥3,980
Day's Low
¥3,907
Volume
10,343,000
Avg. Vol
6,396,403
52-wk High
¥6,693
52-wk Low
¥3,662

Chart for

About

Takeda Pharmaceutical Company Limited is a Japan-based company engaged in the pharmaceutical business. The Ethical Pharmaceutical segment is engaged in the manufacture and sale of pharmaceutical products, such as therapeutic substances for diabetes, circulatory drugs, anticancer drugs, drugs for central neurological diseases,... (more)

Overall

Beta: 0.71
Market Cap(Mil.): ¥4,891,410.00
Shares Outstanding(Mil.): 790.85
Dividend: 90.00
Yield (%): 2.91

Financials

  4502.T Industry Sector
P/E (TTM): 30.36 31.13 34.39
EPS (TTM): 203.74 -- --
ROI: 5.07 15.55 14.96
ROE: 8.38 16.92 16.52

Taisho said to near $1.6 billion deal for Bristol-Myers's UPSA - Bloomberg

Japanese healthcare firm Taisho Pharmaceutical Holdings Co Ltd is said to be close to a $1.6 billion (1.3-billion pound) deal for Bristol-Myers Squibb Co's French over-the-counter drugs business UPSA, Bloomberg reported on Sunday, citing sources familiar with the matter.

6:45am GMT

Takeda clears key hurdle as investors back $59 billion Shire deal

OSAKA Takeda Pharmaceutical has won shareholder approval for its $59 billion takeover of London-listed Shire , creating a global powerhouse that has a stronger drugs pipeline but is also saddled with massive debt. | Video

05 Dec 2018

UPDATE 4-Takeda clears key hurdle as investors back $59 billion Shire deal

* Shares in Shire and Takeda both gain ground (Updates with approval from Shire shareholders)

05 Dec 2018

Takeda investors back $59 billion Shire deal, but wary of debt load

OSAKA Takeda Pharmaceutical shareholders approved on Wednesday its $59 billion (46.3 billion pounds) takeover of London-listed Shire , creating a global powerhouse with a stronger drugs pipeline but one that is saddled with massive debt. | Video

05 Dec 2018

Takeda shareholders approve Shire acquisition - spokesman

TOKYO, Dec 5 Takeda Pharmaceutical shareholders approved on Wednesday its $59 billion takeover of London-listed Shire, a Takeda spokesman said, creating a global powerhouse with a stronger drugs pipeline but one that is saddled with massive debt.

05 Dec 2018

Investor advisory firms back Takeda's $62 billion deal for Shire

LONDON Two shareholder advisory firms have backed Takeda Pharmaceutical's $62 billion (48 billion pounds) takeover offer for drugmaker Shire , dealing a blow to a group of investors who hope to block the deal.

21 Nov 2018

EU approves Takeda buying Shire, on divestment condition

BRUSSELS The European Commission said on Tuesday that it approved the $62-billion (48.2 billion pounds) takeover of London's Shire plc by Takeda Pharmaceutical of Japan, subject to the divestment of a Shire drug in development.

21 Nov 2018

EU approves Takeda buying Shire, on divestment condition

BRUSSELS The European Commission said on Tuesday that it approved the $62-billion takeover of London's Shire plc by Takeda Pharmaceutical of Japan, subject to the divestment of a Shire drug in development.

20 Nov 2018

EU approves Takeda buying Shire, on divestment condition

BRUSSELS, Nov 20 The European Commission said on Tuesday that it approved the $62-billion takeover of London's Shire plc by Takeda Pharmaceutical of Japan, subject to the divestment of a Shire drug in development.

20 Nov 2018

Investor advisory firms back Takeda's $62 billion deal for Shire

LONDON Two shareholder advisory firms have backed Takeda Pharmaceutical's $62 billion takeover offer for drugmaker Shire , dealing a blow to a group of investors who hope to block the deal.

20 Nov 2018

Earnings vs. Estimates